Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine [MMR varicella zoster virus vaccine] to healthy children aged 11 to 21 months

Trial Profile

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine [MMR varicella zoster virus vaccine] to healthy children aged 11 to 21 months

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary)
  • Indications Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Aug 2010 Results published in the European Journal of Pediatrics.
    • 10 Mar 2008 Status changed from in progress to completed. Updated from ClinicalTrials.gov.
    • 02 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top